Natriumaurothiomalat

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H317：Kann allergische Hautreaktionen verursachen.

  H332：Gesundheitsschädlich bei Einatmen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P304+P340：BEI EINATMEN: Die Person an die frische Luft bringen und für ungehinderte Atmung sorgen.

  P321：Besondere Behandlung

Sodium aurothiomalate Chemische Eigenschaften,Einsatz,Produktion Methoden

• R-Sätze Betriebsanweisung:

  R20/21/22:Gesundheitsschädlich beim Einatmen,Verschlucken und Berührung mit der Haut.
  R43:Sensibilisierung durch Hautkontakt möglich.

• S-Sätze Betriebsanweisung:

  S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.

• Physikalische Eigenschaften

  White to yellowish white powder; odorless; metallic taste; highly soluble in water; practically insoluble in ethanol and ether.

• Verwenden

  Medicine (antirheumatic).

• Verwenden

  Sodium aurothiomalate(I) is useful for high mobility group box chromosomal protein 1 western blotting.

• Definition

  White to yellowish-white powder; odorless; metallic taste. Affected by light. Very soluble in water; practically insoluble in alcohol and ether; aqueous solutions are colorless to pale yellow; pH (5% solution) 5.8–6.5.

• Vorbereitung Methode

  Gold(I) thiomalate is prepared by reacting sodium thiomalate with gold(I) halide. It is stored in the dark and otherwise protected from light.

• Trademarks

  Myochrysine (Merck), Aurolate (Pasadena, USA), Myocrisin (Rh?one-Poulenc Rorer, Denmark, Sweden, Finland), Tauredon (BYK Gulden, Germany).

• Pharmazeutische Anwendungen

  Sodium aurothiomalate is a commonly used gold-based DMARD and is indicated for active progressive RA. It is administered by deep intramuscular injection. Administration is started with a test dose of 10mg followed by weekly intervals of 50 mg doses. An improvement is expected to be seen once 300–500 mg is administered. Treatment should be discontinued if there is no improvement after administering 1 g or 2months. Intervals of administration should be gradually increased to 4weeks in patients in whom an effect can be seen. If any blood disorders or other side effects such as GI bleedings or proteinuria are observed, sodium aurothiomalate should be discontinued.

• Clinical Use

  Active progressive rheumatoid arthritis in adults

• Sicherheitsprofil

  Poison by subcutaneous and intramuscular routes. Moderately toxic bj intravenous ' route. Human systemic effects: aggression, agranulocytosis, aplastic anemia, cell count changes, changes in circulation, cholestatic jaunhce, dermatitis, encephalitis, fasciculations, flaccid paralysis without anesthesia, hemorrhage, hepatitis (hepatocellular necrosis), increased body temperature, interstitial fibrosis, muscle weakness, proteinuria, recording from peripheral motor nerve, depressed renal function tests, somnolence, structural changes in nerve sheath, thrombocytopenia, uncharacterized allergc reaction, changes in blood, teeth, and supporting structures. Experimental teratogenic and reproductive effects. When heated to decomposition it emits very toxic Na2O and SOx.

• Synthese

  Synthesis: a solution of thiomalic acid and 3 equivalents of sodium hydroxide are mixed with an aqueous suspension of gold(I) iodide. The product, a mixture of the mono- and disodium salts, is precipitated by the addition of ethanol.
  

• Arzneimittelwechselwirkung

  Potentially hazardous interactions with other drugs
  ACE-inhibitors: flushing and hypotension reported in combination.
  Penicillamine: increased risk of toxicity - avoid.

• Stoffwechsel

  Mainly excreted in the urine with smaller amounts in the faeces.

Natriumaurothiomalat Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(57)Suppliers

12244-57-4, Sodium aurothiomalate Verwandte Suche: